PRODUCT
LT-02, a new and optimized retard formulation of phosphatidylcholin was developed by Lipid Therapeutics.
In the ongoing multicenter multinational clinical phase IIb study the efficacy and safety of LT-02 will be further explored in patients suffering from ulcerative colitis. This study will provide the basis for pivotal clinical phase III studies necessary for registration and marketing approval.